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Simple Summary: Primary central nervous system lymphoma is a rare disease with limited ther-
apeutic options. A more profound understanding of the molecular mechanisms that underlie this
disease has fostered the development of novel therapeutic approaches. Key developments for the
treatment of primary central nervous system lymphoma were made in the field of small molecule
inhibitors, i.e., drugs that were designed to specifically target the molecular backbone of cancer.
Prominent examples include inhibitors of Bruton’s tyrosine kinase or mammalian target of rapamycin,
as well as immune modulatory thalidomide analogues. Along the same lines, another major strain of
drug development for primary central nervous system lymphoma comprises of immune checkpoint
inhibitors, i.e., monoclonal antibodies designed to unleash anti-cancer immune reactions. This re-
view article discusses these ongoing clinical developments, including biological rationale as well as
preliminary toxicity and efficacy, and provides an outlook for future developments.
Abstract: This review article outlines the current development of emerging treatment strategies for
primary central nervous system lymphoma, a rare brain tumor with, thus far, limited therapeutic
options. Small molecule targeted tyrosine kinase inhibitors, immunomodulatory agents, and immune
checkpoint inhibitors will be discussed. The mechanisms of action, results of completed clinical
studies, ongoing clinical trials, and future perspectives are summarized. Among the most promising
clinical developments in the field of CNS lymphomas is ibrutinib, an inhibitor of Bruton’s tyrosine
kinase, which relays activation of nuclear factor kappa B upon integration of constitutive B cell
receptor and Toll-like receptor signals. Down-stream of nuclear factor kappa B, the thalidomide
analogs lenalidomide and pomalidomide exert immunomodulatory functions and are currently
explored against CNS lymphomas. Finally, immune checkpoint inhibitors, such as drugs targeting
the PD-1 pathway, may become novel therapeutic options to unleash anti-tumor immunity in patients
with primary CNS lymphoma.
Keywords: primary CNS lymphoma; PCNSL; ibrutinib; lenalidomide; immune checkpoint inhibition;
PD-1; nivolumab; pembrolizumab
1. Background
Primary central nervous system lymphoma (PCNSL) is an extra-nodal lymphoma
characterized by exclusive localization in the central nervous system, including the lep-
tomeningeal compartment and eyes. PCNSL is rare, accounting for approximately 2% of all
primary brain tumors and less than 1% of non-Hodgkin lymphomas [1]. The incidence of
PCNSL increases with age for unknown reasons, with a median age of 67 years at the time
of diagnosis in the U.S. [1]. The histopathological assessment of the tumor tissue reveals a
diffuse large B cell lymphoma (DLBCL) in the vast majority of cases [2].
Most standard regimens used for the treatment of patients with systemic lymphoma,
such as R-CHOP, were proven inactive against PCNSL, most likely because of the very
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limited blood-brain barrier penetration of these drugs. Whole brain radiotherapy (WBRT)
results in high response rates, but rarely in durable remissions. Furthermore, WBRT
is associated with significant neurotoxicity, particularly in the overall elderly PCNSL
population [3]. It has therefore been largely abandoned as part of first-line therapy and is
now more frequently used as a salvage therapy in patients lacking other treatment options,
with limited activity. High-dose intravenous methotrexate (HD-MTX) has become the
backbone of virtually all treatment regimens for PCNSL as it crosses the blood-brain barrier
and exerts clinically meaningful anti-lymphoma activity. In the last 20 years, most efforts
aimed at improving the outcome of PCNSL patients involves combining HD-MTX with
additional drugs, mostly classical chemotherapeutic agents. Among the drugs which have
been used most frequently are high-dose cytarabine, ifosfamide, thiotepa, procarbazine,
and vincristine. While these combinations have resulted in increased response rates, their
impact on overall survival is less clear, partially because of the limited sample size of the
respective trials [4–6]. WBRT and autologous stem cell transplantation were explored as
a consolidation therapy. WBRT should be avoided, particularly in patients achieving a
complete response, because of its negative impact on cognitive function [7,8]. Stem cell
support may be overall better tolerated and, therefore, be the preferred consolidation
strategy in patients qualifying for such an intense therapy [9,10].
Advances in the understanding of molecular mechanisms which drive PCNSL have
triggered molecularly targeted treatment approaches. The first targeted drug that was
frequently added to HD-MTX-based regimens was rituximab, a monoclonal antibody
targeting CD20. Rituximab was approved for different types of systemic lymphomas with
proven efficacy. While CD20 is expressed on largely all PCNSL, the value of rituximab
against this tumor remains a matter of debate. Due to its overall good tolerability and the
preliminary data from retrospective series which suggested activity against PCNSL, it was
more frequently integrated into treatment protocols for PCNSL [11]. Rituximab was also
added to HD-MTX and cytarabine in the induction part of the IELSG-32 trial. This approach
translated into numerically higher response rates, as well as longer progression-free (PFS)
and overall survival (OS) compared to chemotherapy alone [12]. These findings are in
contrast to an adequately sized, randomized trial where rituximab was added to HD-MTX,
procarbazine, and carmustine. In this study, there was a non-significant trend for longer
PFS in the rituximab group, but no difference in OS between the two treatment arms [13].
Therefore, the role of rituximab in the treatment of PCNSL requires further research. A
more detailed and critical evaluation on the role of rituximab is beyond the scope of this
review and can be found elsewhere [14].
Within the past decade, several drugs have become available for compassionate use in
PCNSL patients based on a continuously improving understanding of the molecular basis
of the disease. Some of these agents have entered advanced-stage clinical development and
may become part of the standard treatment of PCNSL in the future. Since the treatment
of elderly PCNSL patients who are not eligible for an HD-MTX-based regimen remains
a particular challenge [15], novel therapeutic strategies to improve the prognosis of this
continuously increasing patient population are urgently needed. The following sections
provide an overview on the rationale and current clinical development of novel drugs,
which may display anti-tumor activity as single agents or as part of combination regimens
with established chemotherapeutic agents, including small molecule inhibitors of key
oncogenic pathways that underlie PCNSL and immune checkpoint inhibitors designed to
unleash an anti-PCNSL immune response.
2. Targeted Therapies
Different molecular subgroups of DLBCL were defined based on gene expression
profiling and were termed: (i) germinal center B-cell-like (GCB), (ii) activated B-cell-like
(ABC), and (iii) the poorly defined type 3 [16–18]. The oncogenic hallmark of PCNSL is
the activation of the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells),
driven by constitutive activation of signaling through the B cell receptor (BCR) and Toll-like
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receptor (TLR) [19]. PCNSL harbor BCR-activating mutations in CD79B and TLR-activating
mutations in MYD88 at a higher frequency than systemic ABC type DLBCL, whereas
oncogenic mutations in CARD11 and TNFAIP3 occur less frequently in PCNSL [20–24].
MYD88 and CD79B mutations are absent in rare cases of immunosuppression-associated
PCNSL, which are generally driven by the infection of B cells with Epstein-Barr virus [25].
In contrast to systemic DLBCL, MYD88 and CD79B mutations also occur in non-ABC type
PCNSL [21,26]. The frequent loss of chromosome 6q in PCNSL, where the NF-κB inhibitor
TNFAIP3 is encoded, may further contribute to NF-κB activation [27–30]. The BCR/TLR-
NF-κB axis can be targeted at multiple levels: up-stream of NF-κB utilizing small molecule








Figure 1. Schematic of oncogenic drivers of PCNSL. Small molecule inhibitors that are currently
under clinical investigation for PCNSL are highlighted in red. Abbreviations: MYD88, myeloid
differentiation primary response 88; BTK, Bruton’s tyrosine kinase; CARD11, caspase recruitment
domain-containing protein 11; TNFAIP, tumor necrosis factor (TNF)-α-induced protein; NF-κB,
nuclear factor kappa-light-chain-enhancer of activated B cells; IRF4, interferon regulatory factor 4;
CRL4, cullin-RING E3 ubiquitin ligase 4; CRBN, cereblon; PI3K, phosphoinositide 3-kinase; mTOR,
mechanistic target of rapamycin.
2.1. Bruton’s Tyrosine Kinase: Ibrutinib
BCR and TLR signaling converge on the Bruton’s tyrosine kinase (BTK), which inte-
grates both of the signals for subsequent down-stream activation of NF-κB [31]. BTK was
identified as a prime molecular target in PCNSL and the BTK inhibitor ibrutinib has entered
clinical development. In a phase 1/2 study in patients with recurrent or refractory PCNSL,
a maximum tolerated dose of 840 mg daily oral, single-agent ibrutinib was determined and
a clinical response was noted in 10 of 13 patients, including five complete radiographic
responses, yielding a median progression-free survival of 4.6 months [21]. There was a
single patient without clinical response, which was attributed to a CARD11 mutation, a
known mechanism of resistance to ibrutinib [21]. Moreover, CD79B mutations appeared
to convey upregulation of phosphoinositide 3 kinase/mammalian target of rapamycin
(PI3K/mTor) signaling as a potential resistance mechanism [21]. Sequential therapy of
ibrutinib and HD-MTX was also explored in a separate arm of this trial and yielded clin-
ical responses in 12 of 15 patients (80%), and durable response was associated with the
clearance of circulating tumor DNA from the cerebrospinal fluid [32].
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A phase 2 study exploring the tolerability and efficacy of 560 mg daily oral ibrutinib
in 52 patients with PCNSL or ocular lymphoma in the recurrent setting found a median
PFS of 4.8 months [33]. Imaging response was assessed in 42 patients after 2 months of
study treatment and it identified 10 complete responses (19%) and 17 partial responses
(33%), independently of mutations in MYD88 or CD79B [33]. A third study explored
the administration of ibrutinib during a 2-week window of opportunity in 18 patients
with newly diagnosed or recurrent PCNSL, prior to a variety of different chemotherapy
regimens [34]. Although high response rates were reported from this study, weighing the
contribution of ibrutinib is challenging due to the variable subsequent treatments applied
to patients [34].
Overall, ibrutinib was tolerated as a single agent with manageable toxicity that was
resolved upon cessation of treatment, with the most common adverse events being neu-
tropenia, lymphopenia, and three cases of fungal infection among 62 ibrutinib-treated
patients with PCNSL, including one with a fatal outcome [21,33]. By contrast, around 40%
of fungal infections were reported with a combination approach of ibrutinib with different
chemotherapy regimens [34].
There are several ongoing early phase clinical trials of ibrutinib in combination with
standard and experimental drugs in recurrent or refractory PCNSL (Table 1), includ-
ing a randomized phase 2 trial comparing the addition of ibrutinib versus lenalidomide
in combination with MTX, rituximab, and etoposide (NCT04129710). Furthermore, a
phase 2 study explores ibrutinib in the newly diagnosed setting as a maintenance ther-
apy in elderly patients (age 60–85) following induction treatment with HD-MTX plus
rituximab (NCT02623010). The toxicity and preliminary efficacy of the second generation
oral BTK inhibitor acalabrutinib is explored in a phase 1 study, in combination with the
immune checkpoint inhibitor durvalumab, in patients with recurrent or refractory PCNSL
(NCT04462328).
Table 1. Ongoing clinical trials of targeted therapies in PCNSL.
Study Setting Phase Identifier
Randomized clinical trials
Rituximab plus MTX with versus without lenalidomide First line 2 NCT04481815
Maintenance lenalidomide versus procarbazine following induction
therapy with MTX plus rituximab and procarbazine
First line, age ≥ 70 years 2 NCT03495960
R-MPV (MTX, rituximab, procarbazine, and vincristin) plus ibrutinib
versus lenalidomide
First line 2 NCT04446962
MRE (MTX, rituximab, and etoposide) plus ibrutinib versus lenalidomide Recurrent or refractory 2 NCT04129710
Uncontrolled studies
Acalabrutinib plus durvalumab Recurrent or refractory 1 NCT04462328
Rituximab plus ibrutinib plus lenalidomide Recurrent or refractory 1 NCT03703167
MTX and rituximab plus lenalidomide plus nivolumab First line 1 NCT04609046
TEDD (temozolomide, etoposide, doxil, dexamethasone) plus intrathecal
cytarabine plus ibrutinib
Recurrent or refractory 1 NCT02203526
Venetoclax plus obinutuzumab Recurrent or refractory 1 NCT04073147
MTX and rituximab plus lenalidomide First line 1/2 NCT04120350
MTX and rituximab plus ibrutinib Recurrent or refractory 1/2 NCT02315326
Copanlisib plus ibrutinib Recurrent or refractory 1/2 NCT03581942
Rituximab plus pemprolizumab plus ibrutinib Recurrent or refractory 1/2 NCT04421560
Ibrutinib maintenance following induction with MTX and rituximab First line, age 60–85 2 NCT02623010
Rituximab plus lenalidomide First line 2 NCT04627753
MTX, rituximab and temozolomide plus lenalidomide First line 2 NCT04737889
Nivolumab plus ibrutinib Recurrent or refractory 2 NCT03770416
Orelabrutinib Recurrent or refractory 2 NCT04438044
Cancers 2021, 13, 3073 5 of 13
Of note, even though prolonged remissions during treatment with ibrutinib alone are
seen in other lymphoid malignancies, the disease usually recurs promptly after stopping
ibrutinib. Therefore, ibrutinib alone may not be curative, but rather support the efficacy of
combination therapy regimens.
2.2. PI3K/mTor: Temsirolimus, Buparlisib and Bimiralisib
Temsirolimus is an intravenously administered small molecule inhibitor of mTOR
and was explored as single-agent therapy at up to 75 mg weekly in a phase 2 study that
enrolled 37 patients with recurrent or refractory PCNSL [35]. The median age at enrollment
was 70 years and the general condition of patients was good. Temsirolimus yielded an
overall response rate of 54%, including five complete responses and 12 partial responses.
However, responses were usually of short duration, resulting in a median PFS of only
2.1 months at the cost of considerable toxicity, with the most common adverse events
being hyperglycemia, thrombocytopenia, infection, or anemia. This study demonstrated
that mTor inhibition has biological activity in PCNSL, although resistance appears to
evolve rapidly. The low cerebral spinal fluid concentrations of temsirolimus in this study
suggest poor blood-brain barrier penetration and the dependence of efficacy on blood-
brain barrier disruption. Further exploration of mTor as a molecular target in PCNSL
for combination treatment approaches, particularly as a means to overcome resistance to
ibrutinib in CD79B-mutant tumors, may be warranted.
Buparlisib acts up-stream of mTor by inhibition of PI3K and was administered to
four patients with PCNSL, yielding only a single partial response, likely due to limited
penetration of the blood-brain barrier [36]. The buparlisib derivative bimiralisib (PQR309)
is an oral, small molecule inhibitor of both PI3K and mTor that was designed to overcome
this limitation and readily crosses the blood-brain barrier [37,38]. Pre-clinically, the acti-
vation of BCR signaling was associated with anti-lymphoma activity of bimiralisib and
activity against lymphoma cell lines was observed in combination with other targeted
therapies, including rituximab, ibrutinib, lenalidomide, ARV-825, marizomib, venetoclax,
and panobinostat [39]. Bimiralisib obtained orphan drug status by the U.S. Food and Drug
Administration and by the European Medicines Agency for the treatment of PCNSL. Publi-
cation of the results of a phase 2 study of daily oral bimiralisib, that accrued 21 patients
with recurrent or refractory PCNSL, is expected in 2021 (NCT02669511). An ongoing phase
1/2 trial explores the combination of the PI3K inhibitor copanlisib with ibrutinib in patients
with recurrent or refractory PCNSL (NCT03581942).
2.3. Immune Modulatory Small Molecules: Lenalidomide and Pomalidomide
Lenalidomide and pomalidomide are more potent and less toxic brain-penetrating
analogs of the immunomodulatory, anti-angiogenic, and anti-neoplastic oral drug thalido-
mide. Similar to thalidomide, the primary target of both drugs is thought to be cereblon,
the substrate-binding subunit of Cullin-RING E3 ubiquitin ligase 4 (CRL4CRBN), to pro-
mote the degradation of Ikaros lymphocyte differentiation factors [40–42]. The down-
stream effects of lenalidomide and pomalidomide include inhibition of NF-κB [43] and the
PI3K/mTor axis [44], as well as the oncogenic transcription factor and non-GCB marker
IRF4 [45,46], probably indirectly as a result of the physical interaction with cereblon. Be-
yond the cytotoxic effect of lenalidomide and pomalidomide, the microenvironment modu-
lating activity of both drugs includes proinflammatory repolarization of tumor-associated
macrophages [47] and the activation of T cells and natural killer (NK) cells [41,42].
Lenalidomide alone or in combination with rituximab as a salvage therapy approach
was investigated in a phase 1 study in 14 patients with recurrent or refractory PCNSL [48].
This phase 1 study enrolled 14 patients and determined that 15 mg daily of oral lenalido-
mide on 21 of 28 days was the maximum tolerated dose. The overall response rate was
68% and the median PFS was 6 months. Moreover, translational investigations suggested
an association of relapse during lenalidomide therapy with cerebrospinal fluid activity of
the immune tolerance-inducing enzyme indoleamine-2,3 dioxygenase [48,49].
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In a phase 2 clinical trial of lenalidomide in combination with rituximab in 45 patients
with recurrent or refractory PCNSL (n = 34) or primary intravitreal lymphoma (n = 11),
20–25 mg daily of oral lenalidomide was administered on 21 of 28 days with intravenous
rituximab at 375 mg/m2 on day 1 for a total of 8 cycles, followed by maintenance lenalido-
mide at 10 mg daily. Grade 3/4 neutropenia occurred in 20 patients (44%), requiring a
dose reduction in 19, and 15 patients (33%) experienced serious adverse events during
the induction phase. The overall response rate among the 34 patients with PCNSL was
65% and the median PFS was 3.9 months [50]. Higher CD4/CD8 T cell ratios at baseline
were associated with longer PFS, supporting the presumed immunomodulatory effect of
lenalidomide.
Several ongoing clinical trials explore the tolerability and efficacy of lenalidomide in
combination with other standard and experimental treatments (Table 1), including three
randomized phase 2 clinical trials in the first line setting comparing: (i) HD-MTX plus
rituximab with versus without lenalidomide (NCT04481815), (ii) maintenance therapy with
lenalidomide versus procarbazine following induction therapy with MTX plus rituximab
and procarbazine in patients aged ≥ 70 years, and (iii) R-MPV (MTX plus rituximab,
procarbazine and vincristine) plus ibrutinib versus lenalidomide (NCT04446962). Moreover,
one randomized phase 2 trial explores the addition of ibrutinib versus lenalidomide in
combination with MTX, rituximab, and etoposide in the recurrent or refractory setting
(NCT04129710).
In a phase 1 study of pomalidomide in combination with dexamethasone in 29 patients
with recurrent or refractory PCNSL, a maximum tolerated dose of 5 mg daily for 21 days
every 28 days was determined, with the most common grade 3/4 toxicity being neutropenia
in 21% of patients [51]. Among the 25 patients eligible for response assessment, the overall
response rate was 48% and the median PFS was 5.3 months [51].
2.4. Other Molecularly Targeted Agents
Biological rationales exist for other small molecule inhibitors. Bcl-2 is expressed by
the vast majority of PCNSL [52]. The Bcl-2 inhibitor venetoclax obtained approval for
the treatment of chronic lymphatic leukemia [53]. An ongoing phase 1 study is exploring
the feasibility of combined treatment with venetoclax and the anti-CD20 antibody obin-
utuzumab in patients with recurrent or refractory PCNSL (NCT04073147). The cerebral
spinal fluid to plasma ratio of venetoclax in human subjects is in the range of 1:300 [54], in-
dicating a poor crossing of the blood-brain barrier and suggesting that efficacy may depend
on blood-brain barrier disruption. Proteasomal degradation of phosphorylated IkB is a
prerequisite for activation of NF-κB, lending rationale for the brain-penetrating proteasome
inhibitor marizomib [55]. The pre-clinical studies suggest that the silencing of the mutant
MYD88 gene expression can be achieved by utilizing histone deacetylase inhibitors and
that this epigenetic reprogramming exerts synergy with ibrutinib in DLBCL [56,57]. It
needs to be awaited which of these strategies will be investigated in the clinical setting.
3. Immune Checkpoint Inhibitors
3.1. Background
In recent years, drugs targeting the cytotoxic T lymphocyte-associated protein 4
(CTLA-4) or programmed cell death protein 1 (PD-1) pathways have also investigated
in the context of primary and secondary brain tumors. Promising data were obtained
when patients with brain metastasis were treated with immune checkpoint inhibitors [58],
suggesting that the tumor localization in the brain does not preclude the therapeutic activity
of these drugs. In contrast, PD-1 blockade has so far not conferred a survival benefit in
patients with primary brain tumors such as glioblastoma [59]. The rather low expression of
PD-1 and PD-L1 in gliomas, their rather low mutation load, and the immunosuppressive
microenvironment might explain the lack of activity of checkpoint inhibitors. However,
as lymphomas differ significantly from gliomas and other primary brain tumors, it has
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generally been considered a reasonable and promising strategy to test immune checkpoint
inhibitors against PCNSL.
3.2. The Immune Signature of PCNSL
The presence of PD-L1 on tumor cells or PD-1 on tumor-infiltrating bystander cells may
be an important prerequisite for clinical responses to PD-1 blockade [60]. Therefore, several
studies looked at the expression of PD-1 or its ligands in tumor tissue of PCNSL patients
with varying results. Comprehensive genetic analyses revealed copy gain and chromosomal
translocation as key mechanisms of PD-L1 ligand upregulation. In a series of PCNSL, 67%
had 9p24.1/PD-L1/PD-L2 copy gain and copy number-associated increased expression
of the 2 ligands [61]. On the transcriptional level, high PD-1 and PD-L2 expression in
PCNSL tissue specimens were associated with a poor prognosis [62]. On the protein
level, tumor cells in PCNSL tissue specimens were rarely positive for PD-L1 (10%) or
PD-1 (20%). However, 60% of tumor-infiltrating lymphocytes (TIL) were PD-1-positive.
PD-L1-expressing tumor-associated macrophages were found in 20% of tumors. The
authors did not find a correlation between tumor-infiltrating CD8+ T cells and PD-1 or
PD-L1 expression [63]. Another study reported only 4% PD-L1-positive tumor cells in
PCNSL tissue specimens, but 52% of the samples had PD-L1-positive cells in the tumor
microenvironment. PD-L1 expression by tumor cells was associated with longer overall
survival (p = 0.0177), whereas PD-L1 expression on cells in the microenvironment did not
correlate with survival [64]. The expression of PD-L1 in macrophages and microglia cells
infiltrating PCNSL was observed by other authors in a sub-fraction of tumors [65]. In a
series of 48 PCNSL patients, high PD-L1 expression, defined as >5% staining, was found in
37.5% of tumor tissues, and intermediate expression (1–5% staining) was observed in 29.2%.
PD-1 expression was found in 12 of the 14 examined tumors. No correlation between PD-1
and PD-L1 expression was observed [66]. Finally, in a series of 71 PCNSL tumor specimens,
immunohistochemistry revealed PD-1 expression in 16 samples. PD-L1 was present in
42/71 tissues. The authors did not find a correlation between PD-1 or PD-L1 expression
and gender, proliferation rate, or cell of origin [67]. In summary, most data point to a
variable expression of PD-1 and its ligands in a fraction of PCNSL.
Beyond tumor cell-expressed PD-L1, tumor mutational burden (TMB) was considered
a potential predictive marker for response to PD-1 blockade [68]. In PCNSL, a TMB of
≥5 mutations per megabase (mt/Mb) was found in 41/42 tumors. Notably, 8 samples (19%)
displayed high TMB (≥17 mt/Mb) and 71.4% of cases had intermediate TMB (7–16 mt/Mb).
Microsatellite instability was not detected in any sample [66]. High tumor tissue PD-L1
expression was also associated with higher levels of soluble PD-L1 (sPD-L1) in the serum
of PCNSL patients. Furthermore, sPD-L1 serum values in PCNSL patients were higher
than in healthy control subjects. High sPD-L1 levels were associated with an increased risk
for tumor recurrence, as well as shorter PFS and OS [69]. Further analyses are required to
determine whether sPD-L1 may be used as a biomarker to identify patients who are most
likely to derive benefit from PD-1 blockade.
3.3. Efficacy of PD-1 Blockade in Preclinical PCNSL Models
The therapeutic targeting of the PD-1 pathway was tested in a preclinical model of
CNS lymphoma using A20 murine lymphoma cells, which express PD-L1 [70]. Immuno-
competent mice were injected with A20 cells in the left periventricular area. Anti-PD-1
antibodies were administered intraperitoneally weekly starting at day 8 after tumor im-
plantation. The anti-PD-1 treatment resulted in prolonged survival compared to untreated
animals, with 50% of the mice still alive at day 70. The ex vivo analysis of the tumors by im-
munohistochemistry demonstrated a significant increase in tumor-infiltrating CD8+ T cells.
In long-term surviving mice, no lymphoma cells were detectable, suggesting complete
eradication of the tumor upon PD-1 therapy.
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3.4. Clinical Data on Immune Checkpoint Inhibitors in PCNSL
Immune checkpoint inhibitors have not been systematically investigated in PCNSL
thus far and the available evidence relies on small case series and anecdotal reports on the
use of drugs targeting the PD-1 pathway. PD-1/PD-L1 inhibitors may be used as single
agents or in combination with other treatment modalities. As expected, most data on the
use of PD-1 inhibitors in PCNSL comes from patients with recurrent or relapsed tumors, as
no standard of care is established for this situation [71]. Nevertheless, with a growing body
of evidence on their use in PCNSL patients, the upfront use of PD-1 inhibitors or other
immune checkpoint inhibitors may represent a novel therapeutic strategy, which might be
of particular interest for patients who do not qualify for HD-MTX-based regimens.
In a series of four patients with relapsed or refractory PCNSL, and one patient with
CNS relapse of primary testicular lymphoma (PTL), all patients responded to treatment
with the PD-1 inhibitor nivolumab. Four of the patients achieved a complete response,
while one had a partial response. Three of the patients were progression-free for more
than 12 months [72]. The toxicity was mostly mild, including pruritus and fatigue. Renal
insufficiency occurred in one patient and was considered unrelated to the nivolumab
therapy. In general, there was a correlation between mutation load in the tumor tissue
and response to immune checkpoint inhibition [68]. The tumor mutational burden might
be a surrogate marker for the presence of neoantigens recognized by antigen-specific T
cells, which become activated following PD-1 blockade. Terziev et al. identified a PCNSL
patient with a tumor that exhibited high mutational burden [73]. In this particular patient,
immunohistochemistry also revealed the presence of PD-1-positive tumor-infiltrating T
cells. Due to these findings, a decision was made to treat the patient with autologous
transplantation and subsequent nivolumab maintenance therapy, which resulted in a
durable complete remission.
The combination of immune checkpoint inhibitors and other drugs may result in
additional or even synergistic activity, but it also harbors the risk of increased toxicity.
Ambady et al. reported on six patients with refractory or relapsed CNS lymphoma who
were treated with a PD-1 inhibitor and rituximab. Of these six patients, three had systemic
lymphoma with isolated CNS relapse and three had PCNSL that recurred following HD-
MTX-based therapy. Five of the six patients had more than one line of prior therapy. A
complete response was achieved in three patients (50%), which was durable in two of
them. In one patient, progressive disease was diagnosed after the first dose, which led to
additional treatment with WBRT and a subsequent partial response. As with other tumor
entities, the imaging findings might have been misinterpreted as progressive disease but
could have also represented immune checkpoint inhibitor-induced pseudoprogression [74].
A complete remission was also achieved in a PCNSL patient upon the administration of
nivolumab in combination with a dendritic cell vaccination. Despite multiple lines of prior
therapy, this immunotherapeutic concept resulted in a response for 10 months [75].
Graber et al. treated five patients, with primary or secondary CNS lymphoma refrac-
tory, to other therapies with the PD-1 inhibitor pembrolizumab. They observed durable,
complete remissions in two patients, while the other three deteriorated after the first
infusion [76]. In line with these findings, treatment with pembrolizumab resulted in a
partial response in a patient with primary mediastinal B cell lymphoma and CNS involve-
ment [77]. Although comparisons between primary and secondary CNS lymphomas are
limited because of the different underlying biology, these data suggest that lymphoma
manifestations in the CNS are sensitive to PD-1 inhibition. In summary, the available data
support the further development of PD-1/PD-L1 inhibitors against B cell malignancies
involving the CNS.
4. Conclusions
Therapeutic progress in the field of PCNSL has been limited in recent decades, with
most efforts aimed at improving the efficacy of induction therapy and defining the role
of consolidation treatment. Beyond radiation therapy and classical chemotherapeutic
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agents, only the CD20-targeting antibody rituximab was introduced in many treatment
concepts despite the lack of conclusive data on its activity against CNS lymphomas. Novel
therapeutic approaches with targeted agents and immunotherapeutic drugs may be par-
ticularly attractive in elderly or frail patients who are not eligible for protocols involving
HD-MTX. Although comprehensive studies are lacking, these new treatment options may
also have a more favorable toxicity profile, including less detrimental effects on cognitive
function. The impact of novel drugs on neurocognition requires thorough analyses of large
patient cohorts with adequate follow-up [78]. In summary, data from larger and ideally
randomized trials are needed to determine if targeted agents (summarized in Table 1) or
immune checkpoint inhibitors become available for clinical routine in the management of
PCNSL patients. Prospective trials evaluating PD-1 inhibitors in PCNSL are ongoing. The
CheckMate 647 study is a phase 2, open-label, single-arm study, which explores the safety
and efficacy of nivolumab in patients with recurrent or relapsed PCNSL or PTL. The data
of this trial will help in clarifying the role of PD-1 inhibitors in PCNSL and may lead to a
subsequent randomized trial.
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